Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion

Felipe Andreiuolo,Christina K. Ferrone,Sharika Rajan,Arie Perry,Ekin Guney,Elaine Cham,Caterina Giannini,Angus Toland,Nicholas Willard,Andrea Silveira de Souza,Karen Dazelle,Hye-Jung Chung,Omkar Singh,Kyle Conway,Nicholas Coley,Christopher Dampier,Zied Abdullaev,Drew Pratt,Patrick J. Cimino,Martha Quezado,Kenneth Aldape

DOI: https://doi.org/10.1186/s40478-024-01746-7

2024-03-19

Acta Neuropathologica Communications

Abstract:Central nervous system (CNS) embryonal tumors are a heterogeneous group of high-grade malignancies, and the increasing clinical use of methylation profiling and next-generation sequencing has led to the identification of molecularly distinct subtypes. One proposed tumor type, CNS tumor with BRD4::LEUTX fusion, has been described. As only a few CNS tumors with BRD4::LEUTX fusions have been described, we herein characterize a cohort of 9 such cases (4 new, 5 previously published) to further describe their clinicopathologic and molecular features. We demonstrate that CNS embryonal tumor with BRD4::LEUTX fusion comprises a well-defined methylation class/cluster. We find that patients are young (4 years or younger), with large tumors at variable locations, and frequently with evidence of leptomeningeal/cerebrospinal fluid (CSF) dissemination. Histologically, tumors were highly cellular with high-grade embryonal features. Immunohistochemically, 5/5 cases showed synaptophysin and 4/5 showed OLIG2 expression, thus overlapping with CNS neuroblastoma, FOXR2 -activated. DNA copy number profiles were generally flat; however, two tumors had chromosome 1q gains. No recurring genomic changes, besides the presence of the fusion, were found. The LEUTX portion of the fusion transcript was constant in all cases assessed, while the BRD4 portion varied but included a domain with proto-oncogenic activity in all cases. Two patients with clinical follow up available had tumors with excellent response to chemotherapy. Two of our patients were alive without evidence of recurrence or progression after gross total resection and chemotherapy at 16 and 33 months. One patient relapsed, and the last of our four patients died of disease one month after diagnosis. Overall, this case series provides additional evidence for this as a distinct tumor type defined by the presence of a specific fusion as well as a distinct DNA methylation signature. Studies on larger series are required to further characterize these tumors.

neurosciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is related to the molecular and clinicopathological characteristics of a specific type of central nervous system (CNS) embryonal tumor, namely CNS embryonal tumors with BRD4::LEUTX fusion genes. These tumors are relatively rare in clinical practice, and there have been few previously reported cases, so the detailed description and classification of their characteristics are still insufficient. By analyzing 9 cases of such tumors (4 newly reported cases and 5 previously published cases), the author aims to further clarify the molecular and clinicopathological features of these tumors, including their methylation characteristics, immunohistochemical manifestations, gene fusion status, and the clinical prognosis of patients.

Specifically, this study focuses on the following aspects:
1. **Molecular characteristics**: Confirm the existence of BRD4::LEUTX fusion genes and analyze their specific fusion sites in different cases.
2. **Methylation characteristics**: Through methylation profiling analysis, determine whether these tumors form an independent methylation cluster.
3. **Clinicopathological characteristics**: Describe the age of patients, tumor location, histological features, and the expression of immunohistochemical markers, etc.
4. **Clinical prognosis**: Evaluate the patients' response to chemotherapy and survival situation to understand the clinical behavior of this type of tumor.

Through these analyses, the author hopes to provide more evidence for this rare CNS embryonal tumor, support it as an independent tumor type, and provide a basis for further research and clinical treatment.